View PDF Version
 
DOI: 10.1039/A805333B (Paper) Reference Section for: Chem. Commun., 1998, 2141-2142

Enantioselective synthesis of an axially chiral 1,7-naphthyridine-6-carboxamide derivative having potent antagonist activity at the NK1 receptor

(Note: The full text of this document is currently only available in the PDF Version )

Yoshinori Ikeura, Takayuki Doi, Akira Fujishima and Hideaki Natsugari

Abstract

A new and highly potent NK1 antagonist, (aR,9R)-3 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione], was atropdiastereoselectively synthesized in good yield by cyclization of the chiral intermediate 6b.

References

  1. (a) H. Natsugari, Y. Ikeura, Y. Kiyota, Y. Ishichi, T. Ishimaru, O. Saga, H. Shirafuji, T. Tanaka, I. Kamo, T. Doi and M. Otsuka, J. Med. Chem., 1995, 38, 3106 CrossRef CAS; (b) Y. Ikeura, T. Tanaka, Y. Kiyota, S. Morimoto, M. Ogino, T. Ishimaru, I. Kamo, T. Doi and H. Natsugari, Chem. Pharm. Bull., 1997, 45, 1642 CAS; (c) Y. Ikeura, Y. Ishichi, T. Tanaka, A. Fujishima, M. Murabayashi, M. Kawada, T. Ishimaru, I. Kamo, T. Doi and H. Natsugari, J. Med. Chem., in the press Search PubMed.
  2. Recent review articles for tachykinin antagonists: S. MacLean, Med. Res. Rev., 1996, 16, 297 Search PubMed; J. A. Lowe III, Med. Res. Rev., 1996, 16, 527 CrossRef.
  3. The italic letter a before the corresponding R and S denotes an axial chirality as suggested by Cahn et.al.; R. S. Cahn, C. Ingold and V. Prelog, Angew. Chem., Int. Ed. Engl., 1966, 5, 385 Search PubMed.
  4. As for synthesis and separation of atropisomers of some aromatic carboxamides, see S. Thayumanavan, P. Beak and D. P. Curran, Tetrahedron Lett., 1996, 37, 2899 Search PubMed; J. Clayden, N. Westlund and F. X. Wilson, Tetrahedron Lett., 1996, 37, 577 CrossRef CAS; J. Clayden, J. H. Pink and S. A. Yasin, Tetrahedron Lett., 1998, 39, 105 CrossRef CAS; A. Ohno, M. Kashiwagi, Y. Ishihara, S. Ushida and S. Oka, Tetrahedron, 1986, 42, 961 CrossRef CAS.
  5. H. Natsugari, T. Ishimaru, T. Doi, Y. Ikeura and C. Kimura, Eur. Pat. Appl., EP733632, 1996(Chem. Abst., 1997, 126, 8145) Search PubMed.
  6. K. Mori, Tetrahedron, 1983, 39, 3107 CrossRef CAS; H. Mattes, K. Hamada and C. Benezra, J. Med. Chem., 1987, 30, 1948 CrossRef CAS.
  7. As for atropisomerism in seven-membered heterocycles, see N. W. Gilman, P. Rosen, J. V. Earley, C. Cook and L. J. Todaro, J. Am. Chem. Soc., 1990, 112, 3969 Search PubMed.
  8. Crystal data for (aR, 9R)-3: C30H25F6N3O2, M= 573.54, orthorhombic, 0.80 × 0.50 × 0.20 mm, a= 15.727(3), b= 22.972, c= 7.672(3)Å, V= 2771.6(10)Å3, T= 298 K, P212121(#19), Z= 4, µ(Cu-Kα)= 9.59 cm–1, reflections measured = 2386, R= 0.068. CCDC 182/988.
  9. M. A. Cascieri, E. Ber, T. N. Fong, S. Sadowski, A. Basal, C. Swain, E. Seward, B. Frances, D. Burns and C. D. Strader, Mol. Pharmacol., 1992, 42, 458 Search PubMed.
  10. A. Eglezos, S. Giuliani, G. Viti and C. A. Maggi, Eur. J. Pharmacol., 1991, 209, 277 CrossRef CAS.